NCT03795792

Oral Curcumin Administration to Remit Metabolic Syndrome

Completed NA Last updated 17 April 2020

What this trial tests

NA trial testing Curcumin in Metabolic Syndrome in 105 participants. Completed in 6 December 2019.

Timeline

6 May 2018

Primary endpoint
6 August 2019

6 December 2019

Quick facts

Lead sponsor	Coordinación de Investigación en Salud, Mexico
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	105
Start date	6 May 2018
Primary completion	6 August 2019
Estimated completion	6 December 2019
Sites	1 location across Mexico

Drugs / interventions tested

• Curcumin (CURCUMIN) — full drug profile →
• Hydrolyzed collagen

Conditions studied

• Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Coordinación de Investigación en Salud, Mexico — full company profile →

Who can join

Adults 20 to 55, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The metabolic syndrome consists of a set of risk factors that increases the probability to develop heart diseases and type 2 diabetes, two of the principal chronic diseases that affect Mexican population. The curcumin is a compound that is extracted from the root of a plant called Cúrcuma longa. There exists information that curcumin helps to diminish weight and the levels of blood glucose and blood fats. The hypothesis of this study is: that curcumin administration combined with diet and exercise remits the metabolic syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.
   Sivani BM, Azzeh M, Patnaik R, Pantea Stoian A, et al · · 2022 · cited 26× · PMID 35888763 · DOI 10.3390/metabo12070639